Given that overexpression of NKG2D ligands results in regression of thyroid cancer xenografts in vivo, these ligands could be used for cancer vaccine development or gene therapy to generate anti-cancer immune responses. This evidence concerns the gene KLRK1 and thyroid gland carcinoma.